Antifungal therapy in pregnancy and breastfeeding

Current Fungal Infection Reports

Volumn 4, Issue 2, 2010, Pages 62-69

  Njoku, Jessica C ^a   Gumeel, Dalal ^a   Hermsen, Elizabeth D ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Azoles; Breastfeeding; Echinocandins; Fungal infections; Pharmacokinetics; Pregnancy; Safety; Teratogenicity

Indexed keywords

ALLYLAMINE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BUTOCONAZOLE; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POLYENE; POSACONAZOLE; POTASSIUM IODIDE; PYRROLE DERIVATIVE; TERBINAFINE; TERCONAZOLE; TIOCONAZOLE; VORICONAZOLE;

ACIDOSIS; ANTLEY BIXLER SYNDROME; AWARENESS; BLASTOMYCOSIS; BREAST FEEDING; CHILL; COCCIDIOIDOMYCOSIS; CONGENITAL DISORDER; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; EMBRYOTOXICITY; FETUS RISK; HEMATOCRIT; HUMAN; HYPOKALEMIA; LACTATION; LOW DRUG DOSE; MENINGITIS; NEPHROTOXICITY; NONHUMAN; PNEUMONIA; PREGNANCY; REVIEW; SEPTICEMIA; SIDE EFFECT; SPONTANEOUS ABORTION; SPOROTRICHOSIS; SYSTEMIC MYCOSIS; TERATOGENICITY; VAGINA CANDIDIASIS; VISCERAL LEISHMANIASIS;

EID: 79251480612     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0009-7     Document Type: Review

References (47)

1. Merton V: The exclusion of pregnant, pregnable, and oncepregnable people (a.k.a. women) from biomedical research. Am J Law Med 1993, 19(4):369-451.
2. Briggs GG, Freeman RK, Yaffe SJ: A reference guide to fetal and neonatal risk. In Drugs in Pregnancy and Lactation, edn 6. Baltimore: Lippincott Williams & Wilkins; 2002.
3. Moudgal VV, Sobel JD: Antifungal drugs in pregnancy: a review. Expert Opin Drug Saf 2003, 2(5):475-483.
4. FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee. Teratology 1994, 49(6):446-447.
5. Loebstein R, Lalkin A, Koren G: Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997, 33(5):328-343. (Pubitemid 27480937)
6. Anderson GD: Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006, 2(6):947-960.
7. Atkinson HC, Begg EJ, Darlow BA: Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988, 14(4):217-240.
8. King CT, Rogers PD, Cleary JD, et al.: Antifungal therapy during pregnancy. Clin Infect Dis 1998, 27(5):1151-1160. (Pubitemid 29242465)
9. Czeizel AE, Toth M, Rockenbauer M: No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 1999, 10(4):437-440. (Pubitemid 29288244)
10. Nikolov A, Shopova E, Mikhova M, et al.: Treatment in cases of recurrent vaginal candida infection during pregnancy. Akush Ginekol (Sofia) 2007, 46(9):23-26.
11. Czeizel AE, Kazy Z, Puho E: Population-based case-control teratologic study of topical miconazole. Congenit Anom (Kyoto) 2004, 44(1):41-45.
12. Monistat 7 vaginal cream [package insert]. Raritan, NJ: Ortho Pharmaceuticals; 1991.
13. Brent NB: Thrush in the breastfeeding dyad: results of a survey on diagnosis and treatment. Clin Pediatr (Phila) 2001, 40(9):503-506.
14. Nystatin vaginal tablets USP 100,000 units [package insert]. East Hanover, NJ: Odyssey Pharmaceuticals; 2003.
15. Young GL, Jewell D: Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001, 4:CD000225.
16. ACOG Committee on Practice Bulletins-Gynecology: ACOG Practice Bulletin. Clinical management guidelines for obstetrici-angynecologists, Number 72, May 2006: Vaginitis. Obstet Gynecol 2006, 107(5):1195-1206.
17. Centers for Disease Control and Prevention, Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55(RR-11):1-94.
18. Pursley TJ, Blomquist IK, Abraham J, et al.: Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996, 22(2):336-340. (Pubitemid 26056165)
19. Aleck KA, Bartley DL: Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997, 72(3):253-256. (Pubitemid 27424225)
20. Inman W, Pearce G, Wilton L: Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994, 46(2):115-118. (Pubitemid 24101326)
21. Jick SS: Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999, 19(2):221-222.
22. Norgaard M, Pedersen L, Gislum M, et al.: Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother 2008, 62(1):172-176. This study presents evidence suggesting a lack of congenital malformations with low-dose fluconazole therapy during the first trimester. Most subjects (74%) received a total of 150 mg of fluconazole (range 150-600 mg). Congenital malformations were similar to those observed in the general population.
23. Sanchez JM, Moya G: Fluconazole teratogenicity. Prenat Diagn 1998, 18(8):862-863.
24. Chapman SW, Dismukes WE, Proia LA, et al.: Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(12):1801-1812.
25. Wheat LJ, Freifeld AG, Kleiman MB, et al.: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45(7):807-825.
26. American Academy of Pediatrics: Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001, 108(3):776-789.
27. Force RW: Fluconazole concentrations in breast milk. Pediatr Infect Dis J 1995, 14(3):235-236.
28. Bar-Oz B, Moretti ME, Bishai R, et al.: Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am J Obstet Gynecol 2000, 183(3):617-620.
29. De Santis M, Di Gianantonio E, Cesari E, et al.: First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. Drug Saf 2009, 32(3):239-244. This observational study of itraconazole reported increased spontaneous abortion and pregnancy termination after the first trimester. An increased risk of congenital anomalies was not observed. These results warrant follow-up study.
30. Noxafil (posaconazole) oral suspension [package insert]. Kenilworth, NJ: Schering Corporation; 2006.
31. Vfend (voriconazole) tablets and injection [package insert]. New York, NY: Pfizer; 2005.
32. Costa ML, Souza JP, Oliveira Neto AF, et al.: Cryptococcal meningitis in HIV negative pregnant women: case report and review of literature. Rev Inst Med Trop Sao Paulo 2009, 51(5):289-294. This article provides additional data regarding the use of amphotericin B deoxycholate in pregnancy. Maternal toxicity included hypokalemia, but toxicity was not reported in the infant.
33. Ely EW, Peacock JE Jr, Haponik EF, Washburn RG: Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998, 77(3):153-167. (Pubitemid 28290016)
34. Mueller M, Balasegaram M, Koummuki Y, et al.: A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006, 58(4):811-815. (Pubitemid 44390958)
35. Paranyuk Y, Levine G, Figueroa R: Candida septicemia in a pregnant woman with hyperemesis receiving parenteral nutrition. Obstet Gynecol 2006, 107(2 Pt 2):535-537. (Pubitemid 43832679)
36. Pipitone MA, Gloster HM: A case of blastomycosis in pregnancy. J Am Acad Dermatol 2005, 53(4):740-741.
37. Ilett KF, Kristensen JH: Drug use and breastfeeding. Expert Opin Drug Saf 2005, 4(4):745-768. (Pubitemid 40946070)
38. Cappelletty D, Eiselstein-McKitrick K: The echinocandins. Pharmacotherapy 2007, 27(3):369-388. This article presents an in-depth review of the echinocandin class and its potential toxicity in pregnancy. Overall, the three echinocandins are relatively safe and effective agents, but no data exist supporting their use in pregnancy and breastfeeding.
39. Khaled A, Chtourou O, Zeglaoui F, et al.: Tinea faciei: a report on four cases. Acta Dermatovenerol Alp Panonica Adriat 2007, 16(4):170-173.
40. Lamisil (Terbinafine hydrochloride) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2007.
41. Ancobon (Flucytosine) [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals; 2002.
42. Rosa FW, Hernandez C, Carlo WA: Griseofulvin teratology, including two thoracopagus conjoined twins. Lancet 1987, 1(8525):171. (Pubitemid 17015867)
43. Galgiani JN, Ampel NM, Blair JE, et al.: Coccidioidomycosis. Clin Infect Dis 2005, 41(9):1217-1223. (Pubitemid 41532662)
44. Kauffman CA, Bustamante B, Chapman SW, et al.: Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45(10):1255-1265.
45. Pappas PG, Kauffman CA, Andes D, et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.
46. Perfect JR, Dismukes WE, Dromer F, et al.: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50(3):291-322.
47. Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3):327-360. (Pubitemid 351265310)